Last reviewed · How we verify
Finafloxacin hydrochloride
Finafloxacin hydrochloride is a Small molecule drug developed by MerLion Pharmaceuticals GmbH. It is currently in Phase 1 development.
At a glance
| Generic name | Finafloxacin hydrochloride |
|---|---|
| Sponsor | MerLion Pharmaceuticals GmbH |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Effect of Age and Gender on the PK and Tolerability of Finafloxacin (PHASE1)
- First Time in Man Study of Finafloxacin Hydrochloride (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Finafloxacin hydrochloride CI brief — competitive landscape report
- Finafloxacin hydrochloride updates RSS · CI watch RSS
- MerLion Pharmaceuticals GmbH portfolio CI
Frequently asked questions about Finafloxacin hydrochloride
What is Finafloxacin hydrochloride?
Finafloxacin hydrochloride is a Small molecule drug developed by MerLion Pharmaceuticals GmbH.
Who makes Finafloxacin hydrochloride?
Finafloxacin hydrochloride is developed by MerLion Pharmaceuticals GmbH (see full MerLion Pharmaceuticals GmbH pipeline at /company/merlion-pharmaceuticals-gmbh).
What development phase is Finafloxacin hydrochloride in?
Finafloxacin hydrochloride is in Phase 1.